Subgroup Findings on Brensocatib for Non-Cystic Fibrosis Bronchiectasis, with James D. Chalmers, MBChB, PhD

Subgroup Findings on Brensocatib for Non-Cystic Fibrosis Bronchiectasis, with James D. Chalmers, MBChB, PhD

This interview highlights the subgroup analysis findings of the ASPEN trial, specifically on brensocatib for non-cystic fibrosis bronchiectasis.

Understanding Subgroup Analysis in Clinical Research

Subgroup analysis in clinical research reveals how products perform in specific groups, helping brands create targeted, science-backed product claims.